Bayer stock forecast: Third-party price targets
Bayer AG is a Germany-based life sciences company listed in Frankfurt, operating across pharmaceuticals, crop science and consumer health. Explore third-party BAYN price targets and technical analysis.
Bayer AG (BAYN) is trading around €45.80 as of 4:41pm UTC on 18 February 2026, moving within an intraday range of €43.50-€49.30 on Capital.com’s market data feed. The latest price action follows a sharp pullback from earlier session highs, set against a backdrop of elevated volatility linked to company-specific headlines and broader European equity moves. Past performance is not a reliable indicator of future results.
The stock is trading under pressure after Bayer announced a proposed $7.25bn class-action settlement framework to address Roundup weedkiller cancer claims in the US (BBC News, 17 February 2026). The plan would lift total litigation provisions to about €11.8bn and suggests higher litigation-related cash outflows in 2026. Shares in Frankfurt were reported down between about 5.8% and nearly 8% over 17-18 February as investors assessed the potential impact on free cash flow, leverage, and the delayed publication of 2025 results and 2026 guidance until early March (Morningstar, 18 February 2026).
Bayer stock forecast 2026–2030: Third-party price targets
As of 18 February 2026, third-party Bayer stock predictions show a wide range of 12-month views. The snapshots below summarise selected third-party targets and consensus markers from recent broker and data-vendor updates.
Jefferies (broker research update)
Jefferies maintains a BAYN stock forecast of €25 per share with a Hold rating. The analyst says this reflects expectations of negative free cash flow in 2026 linked to settlement payments, alongside ongoing risks around court approval of the US class settlement and the Supreme Court review of the Durnell case (MarketScreener, 17 February 2026).
Fintel (consensus snapshot, Italy listing)
Fintel reports that the average one-year price target for Bayer Aktiengesellschaft (1BAYN) was revised to about €42.20 per share. The service notes that the latest targets range from roughly €23.14 to €57.54 per share, with dispersion reflecting differing assumptions on earnings recovery, litigation cash outflows, and leverage (Nasdaq, 4 February 2026).
MarketWatch (US OTC consensus)
MarketWatch’s Bayer AG (BAYZF) analyst estimates page shows a high 12-month target of $16.38 and a low of $6.71, translating into an average of around $13.10. The overview cites inputs from multiple covering analysts as they weigh potential earnings normalisation against litigation and balance-sheet risks (MarketWatch, 18 February 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
BAYN stock price: Technical overview
The BAYN stock price is trading around €45.80 as of 4:41pm UTC on 18 February 2026. The price is holding just above its 20-day and 50-day simple moving averages near €45 and €41, while the 100- and 200-day SMAs sit lower at around €35 and €31 respectively. The 14-day RSI stands in the upper-neutral zone near 56, and the ADX at around 45 indicates a firm trend environment rather than overbought conditions.
On the upside, the nearest classic pivot resistance sits around €48.57. A sustained daily close above this level would bring the next reference near €52.58 into focus. On pullbacks, the classic pivot at about €42.72 marks initial support. Below this, the €38.71 S1 area and the 100-day SMA around €34.61 represent additional technical reference points (TradingView, 18 February 2026).
This technical analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Bayer share price history (2024–2026)
BAYN’s stock price has fluctuated over the past two years, moving from the low-€20s in early 2025 to the mid-€40s by February 2026. The stock traded around €21.70 on 18 February 2025, then moved higher through the rest of the year, with a notable advance from roughly €20-€21 in April 2025 to above €30 by December, closing at €30.50 on 1 December 2025.
In early 2026, the pace of gains increased. Bayer rose from about €38.05 at the start of January to the mid-€40s by late month, before reaching an intraday high near €48.90 and finishing at €45.80 on 18 February 2026 – more than twice its level on the same date a year earlier.
Past performance is not a reliable indicator of future results.
Bayer (BAYN): Capital.com analyst view
Bayer’s share price has moved from the low-€20s in early 2025 to around €45.80 by 18 February 2026, as investors reassessed the group’s litigation exposure related to Roundup and its broader earnings outlook. Recent trading has been volatile, with the stock rising into the high-€40s before easing back as markets weighed the potential reduction in legal uncertainty against the cost and timing of proposed settlements and their effect on cash flow and leverage.
Headlines around Bayer’s plan to address US glyphosate claims through a proposed $7.25bn class-action settlement have been a central focus. The framework could clarify part of the legal outlook and allow greater attention on the company’s pharmaceutical and crop-science operations. At the same time, guidance for roughly €5bn of litigation-related payouts in 2026 and an expected negative free cash flow highlight balance-sheet considerations. The pending US Supreme Court review also introduces a range of possible legal outcomes, which could either reduce or extend the litigation process.
Capital.com’s client sentiment for Bayer CFDs
As of 18 February 2026, Capital.com client positioning in Bayer CFDs is highly skewed towards long positions, with buyers at 94.2% and sellers at 5.8%. This leaves buyers ahead by around 88.4 percentage points. This snapshot reflects open positions on Capital.com and can change over time.
Summary – Bayer 2026
- Bayer’s share price more than doubled over the past year, rising from about €21.70 on 18 February 2025 to €45.80 on 18 February 2026.
- Technical indicators show the price holding above its 50-, 100-, and 200-day moving averages, with RSI in upper-neutral territory and ADX indicating a firm trend backdrop.
- Key price drivers include the proposed $7.25bn Roundup settlement, expectations for 2026 cash flows and leverage, and evolving assessments of Bayer’s pharmaceutical and crop-science pipelines.
- Recent coverage has centred on the proposed US glyphosate settlement structure and the pending US Supreme Court proceedings, both of which could influence the duration and cost of ongoing litigation.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Bayer stock?
Bayer is a publicly listed company, and its shares are held by a mix of institutional and retail investors. Large global asset managers and investment funds typically account for a significant portion of total ownership, alongside pension funds and other financial institutions. Ownership levels may change over time as investors rebalance their portfolios. You can review the latest shareholder breakdown in Bayer’s annual report or through regulatory filings.
What is the 5-year Bayer share price forecast?
There is no single agreed five-year BAYN stock forecast. Most publicly available analyst estimates focus on 12-month price targets rather than longer horizons. Longer-term projections depend on variables such as litigation outcomes, earnings trends, debt levels, and performance across Bayer’s pharmaceutical and crop-science divisions. Because these factors can change, any long-term forecast is inherently uncertain and should be viewed as indicative rather than definitive.
Is Bayer a good stock to buy?
Whether Bayer is considered a ‘good’ stock depends on your individual objectives, risk tolerance, and time horizon. The company faces ongoing litigation risks linked to glyphosate claims, alongside balance-sheet considerations and earnings variability. At the same time, analysts assess its pharmaceutical pipeline and crop-science operations within their valuation frameworks. Investors typically weigh potential upside against legal, financial, and market risks before making decisions. This assessment will differ from one investor to another.
Could Bayer stock go up or down?
Like any listed share, Bayer’s stock price can move up or down in response to company-specific developments and broader market conditions. Litigation updates, earnings results, guidance revisions, regulatory decisions, and shifts in investor positioning can all influence price movements. Macroeconomic conditions and sector trends may also play a role. Share prices are inherently volatile, and past performance does not guarantee future results.
Should I invest in Bayer stock?
Deciding whether to invest in Bayer stock depends on your financial situation, investment goals, and tolerance for risk. Equity investments can offer potential returns, but they also expose you to capital loss. Before investing, many individuals review financial statements, analyst research, and risk disclosures, and some choose to seek independent financial advice. This information is provided for educational purposes only and does not constitute investment advice.
Can I trade Bayer CFDs on Capital.com?
Yes, you can trade Bayer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.